Name | Title | Contact Details |
---|---|---|
Jesse Bishop |
Vice President, Regulatory | Profile |
Bradley Ottinger |
General Counsel and Chief Compliance Officer | Profile |
Gregory Freitag |
General Counsel | Profile |
Marc Began |
Executive Vice President and General Counsel | Profile |
Changing lives with next generation peptide therapeutics
Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. Relypsa was founded in October 2007 and is headquartered in Redwood City, Calif. In 2015, we received FDA approval for our first medicine, which was developed based on our polymer technology platform for the treatment of hyperkalemia. In September 2016, Relypsa became a Vifor Pharma company. Today, we have more than 400 employees united by a passion for improving people’s lives.
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.
Advanced imaging, fluidics, chemistry and bioinformatics. Innovative, robust tools for spatial omics without compromise. Rebus Esper platform available now.
Transave is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.